305 related articles for article (PubMed ID: 31862616)
21. Chemotherapy of Chagas' disease: status and new developments.
Cerecetto H; González M
Curr Top Med Chem; 2002 Nov; 2(11):1187-213. PubMed ID: 12171581
[TBL] [Abstract][Full Text] [Related]
22. Current drug therapy and pharmaceutical challenges for Chagas disease.
Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
[TBL] [Abstract][Full Text] [Related]
23. Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
de Oliveira Filho GB; Cardoso MVO; Espíndola JWP; Oliveira E Silva DA; Ferreira RS; Coelho PL; Anjos PSD; Santos ES; Meira CS; Moreira DRM; Soares MBP; Leite ACL
Eur J Med Chem; 2017 Dec; 141():346-361. PubMed ID: 29031078
[TBL] [Abstract][Full Text] [Related]
24. Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies.
Palos I; Lara-Ramirez EE; Lopez-Cedillo JC; Garcia-Perez C; Kashif M; Bocanegra-Garcia V; Nogueda-Torres B; Rivera G
Molecules; 2017 Jun; 22(6):. PubMed ID: 28629155
[TBL] [Abstract][Full Text] [Related]
25. [The chemotherapy of Chagas disease].
Stoppani AO
Medicina (B Aires); 1999; 59 Suppl 2():147-65. PubMed ID: 10668258
[TBL] [Abstract][Full Text] [Related]
26. Biological factors that impinge on Chagas disease drug development.
Francisco AF; Jayawardhana S; Lewis MD; Taylor MC; Kelly JM
Parasitology; 2017 Dec; 144(14):1871-1880. PubMed ID: 28831944
[TBL] [Abstract][Full Text] [Related]
27. New drugs for neglected infectious diseases: Chagas' disease.
Machado FS; Tanowitz HB; Teixeira MM
Br J Pharmacol; 2010 May; 160(2):258-9. PubMed ID: 20423339
[TBL] [Abstract][Full Text] [Related]
28. The effect of benznidazole dose among the efficacy outcome in the murine animal model. A quantitative integration of the literature.
Molina I; Perin L; Aviles AS; de Abreu Vieira PM; da Silva Fonseca K; Cunha LM; Carneiro CM
Acta Trop; 2020 Jan; 201():105218. PubMed ID: 31610148
[TBL] [Abstract][Full Text] [Related]
29. Chagas Disease Chemotherapy: What Do We Know So Far?
Zuma AA; de Souza W
Curr Pharm Des; 2021; 27(38):3963-3995. PubMed ID: 33593251
[TBL] [Abstract][Full Text] [Related]
30. Therapeutical approaches under investigation for treatment of Chagas disease.
Bahia MT; Diniz Lde F; Mosqueira VC
Expert Opin Investig Drugs; 2014 Sep; 23(9):1225-37. PubMed ID: 24855989
[TBL] [Abstract][Full Text] [Related]
31. Experimental and Clinical Treatment of Chagas Disease: A Review.
Sales Junior PA; Molina I; Fonseca Murta SM; Sánchez-Montalvá A; Salvador F; Corrêa-Oliveira R; Carneiro CM
Am J Trop Med Hyg; 2017 Nov; 97(5):1289-1303. PubMed ID: 29016289
[TBL] [Abstract][Full Text] [Related]
32. Computational Drug Repositioning by Target Hopping: A Use Case in Chagas Disease.
Haupt VJ; Aguilar Uvalle JE; Salentin S; Daminelli S; Leonhardt F; Konc J; Schroeder M
Curr Pharm Des; 2016; 22(21):3124-34. PubMed ID: 26873186
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo trypanocidal activity of a benzofuroxan derivative against Trypanosoma cruzi.
Dos Santos Petry L; Pillar Mayer JC; de Giacommeti M; Teixeira de Oliveira D; Razia Garzon L; Martiele Engelmann A; Magalhães de Matos AFI; Dellaméa Baldissera M; Dornelles L; Melazzo de Andrade C; Gonzalez Monteiro S
Exp Parasitol; 2021; 226-227():108125. PubMed ID: 34129877
[TBL] [Abstract][Full Text] [Related]
34. Tackling the challenges of human Chagas disease: A comprehensive review of treatment strategies in the chronic phase and emerging therapeutic approaches.
Ramos LG; de Souza KR; Júnior PAS; Câmara CC; Castelo-Branco FS; Boechat N; Carvalho SA
Acta Trop; 2024 Aug; 256():107264. PubMed ID: 38806090
[TBL] [Abstract][Full Text] [Related]
35. An update on benznidazole for the treatment of patients with Chagas disease.
Thakare R; Dasgupta A; Chopra S
Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
[TBL] [Abstract][Full Text] [Related]
36. Time and dose-dependence evaluation of nitroheterocyclic drugs for improving efficacy following Trypanosoma cruzi infection: A pre-clinical study.
Mazzeti AL; Diniz LF; Gonçalves KR; Nascimento AFS; Spósito PAF; Mosqueira VCF; Machado-Coelho GLL; Ribeiro I; Bahia MT
Biochem Pharmacol; 2018 Feb; 148():213-221. PubMed ID: 29309767
[TBL] [Abstract][Full Text] [Related]
37. Current status of Chagas disease chemotherapy.
Guedes PM; Silva GK; Gutierrez FR; Silva JS
Expert Rev Anti Infect Ther; 2011 May; 9(5):609-20. PubMed ID: 21609270
[TBL] [Abstract][Full Text] [Related]
38. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
[TBL] [Abstract][Full Text] [Related]
39. Trypanocidal treatment of Chagas disease.
Pérez-Molina JA; Crespillo-Andújar C; Bosch-Nicolau P; Molina I
Enferm Infecc Microbiol Clin (Engl Ed); 2021 Nov; 39(9):458-470. PubMed ID: 34736749
[TBL] [Abstract][Full Text] [Related]
40. Repositioning of leishmanicidal [1,2,3]Triazolo[1,5-a]pyridinium salts for Chagas disease treatment: Trypanosoma cruzi cell death involving mitochondrial membrane depolarisation and Fe-SOD inhibition.
Martín-Escolano R; Martín-Escolano J; Ballesteros-Garrido R; Cirauqui N; Abarca B; Rosales MJ; Sánchez-Moreno M; Ballesteros R; Marín C
Parasitol Res; 2020 Sep; 119(9):2943-2954. PubMed ID: 32607710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
